

ANTIGENICS INC /DE/  
Form S-8  
May 28, 2004

**Table of Contents**

As filed with the Securities and Exchange Commission on May 28, 2004

Registration No. 333-\_\_\_\_\_

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

---

**FORM S-8**

REGISTRATION STATEMENT  
UNDER  
THE SECURITIES ACT OF 1933

---

**ANTIGENICS INC.**

(Exact name of registrant as specified in its charter)

**Delaware**  
State or other jurisdiction  
of incorporation or organization)

**06-1562417**  
(I.R.S. Employer  
Identification No.)

Antigenics Inc.  
630 Fifth Avenue, Suite 2100  
New York, NY 10111  
(Address of principal executive offices, including zip code)

---

**1999 EQUITY INCENTIVE PLAN**  
(Full title of the plan)

Garó H. Armen  
Antigenics Inc.  
630 Fifth Avenue, Suite 2100  
New York, NY 10111  
212-994-8200  
(Name, address and telephone number, including area code, of agent for service)

---

Please send copies of all communications to:

Paul M. Kinsella  
Ropes & Gray LLP  
One International Place  
Boston, MA 02110  
617-951-7000  
617-951-7050 (facsimile)

<b>Title of Each Class of Securities to be</b>	<b>Amount to be</b>	<b>Proposed Maximum Offering Price Per</b>	<b>Proposed Maximum Aggregate Offering</b>	<b>Amount of</b>
--	---------------------	--	--	------------------

<b>Registered</b>	<b>Registered</b>	<b>Share(1)</b>	<b>Price(1)</b>	<b>Registration Fee</b>
Common Stock, \$0.01 par value per share	4,000,000 shares(2)	\$ 8.35	\$33,400,000.00	\$4,231.78

- (1) Pursuant to Rules 457(c) and 457(h)(1) under the Securities Act of 1933, the proposed maximum offering price per share and the maximum aggregate offering price for the shares have been calculated solely for the purpose of computing the registration fee on the basis of the average high and low prices of the Common Stock as reported by the Nasdaq National Market on May 24, 2004 to be \$8.60 and \$8.09, respectively.
- (2) Pursuant to Rule 416(a) under the Securities Act of 1933, this registration statement also covers such additional shares of Common Stock as may be issued to prevent dilution from stock splits, stock dividends and similar transactions.

**TABLE OF CONTENTS**

SIGNATURES

OPINION OF ROPES & GRAY LLP.

AMENDMENT #2 TO 1999 EQUITY INCENTIVE PLAN

CONSENT OF KPMG LLP

---

**Table of Contents**

Explanatory Note

The Registrant hereby increases the number of shares of its Common Stock available for issuance under the 1999 Equity Incentive Plan (the Plan ) by 4 million shares so that a total of 10 million shares will be available under the Plan. Pursuant to Instruction E to Form S-8, the Registrant incorporates by reference into this Registration Statement the entire contents of its Registration Statement on Form S-8 (File No. 333-40442) filed with the Securities and Exchange Commission on June 29, 2000 and amended on June 11, 2003.

---

**Table of Contents**

**SIGNATURES**

Pursuant to the requirements of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of New York, State of New York, on this 28th day of May, 2004.

ANTIGENICS INC.

By: /s/ Garo H. Armen

---

Name: Garo H. Armen  
 Title: Chief Executive Officer

Each person whose signature appears below constitutes and appoints Garo H. Armen his true and lawful attorney-in-fact and agent, with full power of substitution and resubstitution, severally, for him and in his name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this Registration Statement, and to file the same, with all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorney-in-fact and agent full power and authority to do and perform each and every act and thing requisite and necessary to be done, as fully to all intents and purposes as he might or could do in person, hereby ratifying and confirming all that said attorney-in-fact and agent or his substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Act of 1933, this Registration Statement has been signed by the following persons in the capacities indicated and on May 28, 2004.

<b>Signature</b>	<b>Title</b>
/s/ Garo H. Armen, Ph.D. <hr/> Garo H. Armen, Ph.D.	Chief Executive Officer and Chairman of the Board of Directors (Principal Executive Officer, Principal Financial Officer, and Principal Accounting Officer)
/s/ Noubar Afeyan, Ph.D. <hr/> Noubar Afeyan, Ph.D.	Director
/s/ Frank AtLee <hr/> Frank AtLee	Director
/s/ Gamil de Chadarevian <hr/> Gamil de Chadarevian	Director, Vice Chairman of the Board



**Table of Contents**

/s/ Tom Dechaene

Tom Dechaene Director

/s/ Margaret Eisen

Margaret Eisen Director

/s/ Wadih Jordan

Wadih Jordan Director

/s/ Mark Kessel

Mark Kessel Director

/s/ Pramod Srivastava

Pramod Srivastava Director

---

**Table of Contents**

**EXHIBIT INDEX**

- 5.1 Opinion of Ropes & Gray LLP.
- 10.1 Antigenics Inc. Amendment No. 2 to 1999 Equity Incentive Plan.
- 23.1 Consent of KPMG LLP.
- 23.2 Consent of Ropes & Gray LLP (included in the opinion filed as Exhibit 5.1).